Turner William D. 4
4 · Sierra Oncology, Inc. · Filed Jul 1, 2022
Insider Transaction Report
Form 4
Turner William D.
Chief Reg & Tech Ops Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2022-07-01−35,000→ 0 totalExercise: $31.54Exp: 2032-03-14→ Common Stock (35,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−75,000→ 0 totalExercise: $12.05Exp: 2030-08-04→ Common Stock (75,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−49,000→ 0 totalExercise: $12.15Exp: 2030-08-12→ Common Stock (49,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2022-07-01−12,300→ 0 totalExercise: $16.73Exp: 2031-03-15→ Common Stock (12,300 underlying)
Footnotes (5)
- [F1]The option vested as to 25% of the total shares on August 4, 2021, and then the remaining shares vest in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F2]Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
- [F3]On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria.
- [F4]The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date.
- [F5]The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date.